Wikipedia
Search Wikipedia:

Latest topics
» Catalysis and its importance in chemical industry
Thu Nov 09, 2017 5:06 am by bejoy

» Cracking: Breaking up larger molecules
Thu Nov 09, 2017 5:05 am by bejoy

» What is Alkylation?
Fri Nov 03, 2017 12:35 am by bejoy

» An Ultimate Guide on Diamond
Thu Nov 02, 2017 2:15 am by bejoy

» Chemistry Running Behind Anger
Mon Oct 30, 2017 12:31 am by bejoy

» The Discovery of Four New Elements in the Periodic Table
Wed Oct 25, 2017 1:23 am by bejoy

» Carbonic Acid: Occurrence, Preparation, Properties and Uses
Mon Oct 23, 2017 1:39 am by bejoy

» Manufacturing of alumina through Bayer process
Tue Oct 17, 2017 1:16 am by bejoy

» Lithium batteries to run at ultra-low temperatures
Thu Oct 12, 2017 12:54 am by bejoy

November 2017
MonTueWedThuFriSatSun
  12345
6789101112
13141516171819
20212223242526
27282930   

Calendar Calendar

Free Hit Counter

Epalrestat effects on diabetic neuropathy

View previous topic View next topic Go down

Epalrestat effects on diabetic neuropathy

Post  kokoblue on Tue Apr 27, 2010 1:53 am

Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease.

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.

Recently, three aldose reductase inhibitors—Epalrestat, fidarestat, and ranirestat— have been evaluated in placebo-controlled clinical trials. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. It is the only drug available in the aldose reductase inhibitor class and was approved in Japan in 1992.

kokoblue

Posts : 15
Join date : 2010-04-21

View user profile

Back to top Go down

View previous topic View next topic Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum